-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Artemis Therapeutics Inc. (OTCMKTS:ATMS) Short Interest Update
Artemis Therapeutics Inc. (OTCMKTS:ATMS) Short Interest Update
Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,300 shares, a decline of 27.8% from the June 15th total of 1,800 shares. Based on an average daily volume of 900 shares, the days-to-cover ratio is presently 1.4 days.
Artemis Therapeutics Price Performance
Artemis Therapeutics stock opened at $3.75 on Monday. Artemis Therapeutics has a twelve month low of $0.55 and a twelve month high of $6.00. The stock's fifty day simple moving average is $3.59 and its 200-day simple moving average is $2.02.
Get Artemis Therapeutics alerts:Artemis Therapeutics (OTCMKTS:ATMS – Get Rating) last posted its quarterly earnings data on Monday, May 23rd. The company reported ($0.01) earnings per share for the quarter.
About Artemis Therapeutics
(Get Rating)Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.
See Also
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- Financial services firm Block stock has fallen (-59%) in 2022
- Hold Pfizer Today With Catalysts for Further Growth Tomorrow
- NVIDIA Stock is a Winding Up for a Record Setting Second Half
- Johnson & Johnson Continues to Prove its Value in a Volatile Year
- MarketBeat: Week in Review 7/11 – 7/15
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,300 shares, a decline of 27.8% from the June 15th total of 1,800 shares. Based on an average daily volume of 900 shares, the days-to-cover ratio is presently 1.4 days.
Artemis治疗公司(场外交易代码:ATMS-GET Rating)6月份空头股数销量大幅下降。截至6月30日,空头股数共有1,300股,较6月15日的1,800股下跌27.8%。以日均成交量900股计算,目前天数与回补比率为1.4天。
Artemis Therapeutics Price Performance
Artemis治疗药物的性价比
Artemis Therapeutics stock opened at $3.75 on Monday. Artemis Therapeutics has a twelve month low of $0.55 and a twelve month high of $6.00. The stock's fifty day simple moving average is $3.59 and its 200-day simple moving average is $2.02.
Artemis治疗公司的股票周一开盘报3.75美元。Artemis治疗公司的12个月低点为0.55美元,12个月高位为6.00美元。该股的50日简单移动均线为3.59美元,200日简单移动均线为2.02美元。
Artemis Therapeutics (OTCMKTS:ATMS – Get Rating) last posted its quarterly earnings data on Monday, May 23rd. The company reported ($0.01) earnings per share for the quarter.
Artemis治疗公司(OTCMKTS:ATMS-GET Rating)最近一次公布季度收益数据是在5月23日星期一。该公司公布了本季度每股收益(0.01美元)。
About Artemis Therapeutics
关于Artemis Treateutics
Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.
Artemis治疗公司没有重大的手术。此前,它参与了严重和危及生命的传染病预防和治疗试剂的开发。该公司总部设在纽约,纽约州。Artemis治疗公司是Tonak有限公司的子公司。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- Financial services firm Block stock has fallen (-59%) in 2022
- Hold Pfizer Today With Catalysts for Further Growth Tomorrow
- NVIDIA Stock is a Winding Up for a Record Setting Second Half
- Johnson & Johnson Continues to Prove its Value in a Volatile Year
- MarketBeat: Week in Review 7/11 – 7/15
- 免费获取StockNews.com关于Artemis治疗(ATMS)的研究报告
- 金融服务公司Block股价在2022年下跌(-59%)
- 今天持有辉瑞公司的催化剂,明天就能实现进一步增长
- NVIDIA股票将在下半年创下纪录
- 强生在动荡的一年里继续证明自己的价值
- MarketBeat:回顾一周7/11-7/15
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Artemis治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Artemis治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧